



APOBEC3B can impair genomic stability by inducing base substitutions in genomic DNA in human cells

Masanobu Shinohara, Katsuhiko Ito, Keisuke Shindo, Masashi Matsui, Takashi Sakamoto, Kohei Tada, Masayuki Kobayashi, Norimitsu Kadowaki & Akifumi Takaori-Kondo

Department of Hematology and Oncology, Graduate school of medicine, Kyoto University, Kyoto 606-8507, Japan.

SUBJECT AREAS:

CANCER GENOMICS

HAEMATOLOGICAL CANCER

DNA DAMAGE AND REPAIR

ONCOGENES

Received
2 August 2012

Accepted
10 October 2012

Published
13 November 2012

Correspondence and
requests for materials
should be addressed to
K.S. (shind009@kuhp.
kyoto-u.ac.jp)

Human APOBEC3 proteins play pivotal roles in intracellular defense against viral infection by catalyzing deamination of cytidine residues, leading to base substitutions in viral DNA. Activation-induced cytidine deaminase (AID), another member of the APOBEC family, is capable of editing immunoglobulin (Ig) and non-Ig genes, and aberrant expression of AID leads to tumorigenesis. However, it remains unclear whether APOBEC3 (A3) proteins affect stability of human genome. Here we demonstrate that both A3A and A3B can induce base substitutions into human genome as AID can. A3B is highly expressed in several lymphoma cells and somatic mutations occur in some oncogenes of the cells highly expressing A3B. Furthermore, transfection of *A3B* gene into lymphoma cells induces base substitutions in *cMYC* gene. These data suggest that aberrant expression of A3B can evoke genomic instability by inducing base substitutions into human genome, which might lead to tumorigenesis in human cells.

It is widely recognized that the accumulation of genetic changes in tumor-related genes is essential for cancer development¹. With the innovation of high-throughput sequencing technology, genome-wide analyses on various types of cancer cells have revealed numerous somatic mutations in tumor-related genes². Some of these mutations are caused by defects in DNA repair systems (e.g., DNA mismatch repair deficiencies give rise to hereditary non-polyposis colon cancer³), whereas mechanisms that account for the majority of genetic changes in cancer cells are poorly understood. Referring to somatic base substitution spectra in cancer cells, C/G to T/A transitions are most prevalent, especially in gastric cancer, colorectal cancer, glioma, and melanoma^{2,4,5}. This strong bias in somatic mutations suggests the existence of active mechanisms that induce C/G to T/A transitions into genomic DNA. It is obviously attributable to ultraviolet irradiation and following repair process against pyrimidine dimer in case of melanoma, but not in others.

The human APOBEC family proteins can induce C to T (G to A, in complementary sequences) transitions into target DNA through cytidine deamination. The APOBEC family is comprised of a series of molecules with conserved cytidine deaminase domains (CDAs), including AID, APOBEC1, APOBEC2, APOBEC3A to H, and APOBEC4^{6,7}. Among them, AID plays a crucial role in somatic hypermutation and class switch recombination of Ig genes, which enables diversification of immune system⁸. AID has been considered the only molecule that can induce C/G to T/A transitions into genomic DNA. The expression of AID is highly regulated and restricted in germinal center B-cells under physiological conditions, but with inflammatory stimulations, AID can be overexpressed in not only B-cells but also other types of cells (e.g., epithelial cells) via activation of NF- κ B⁹. Aberrant expression of AID results in the accumulation of mutations in non-Ig genes¹⁰, which leads to development of various cancers such as gastric and hepatic cancers as well as lymphomas^{9,11–13}.

A series of seven A3 genes are tandemly arrayed on human chromosome 22, and the main function of the resulting gene products is to protect the cells from retroviruses and endogenous mobile retroelements^{14,15}. A3B, A3D, A3F, and A3G contain two CDAs, instead of one in A3A, A3C, and A3H. A3G is a powerful anti-retroviral molecule that induces cytidine deamination in viral genome and acts as a host defensive factor against viruses such as HIV-1¹⁶. A3A and A3B have been reported as potent inhibitors of retrotransposons¹⁷. Thus, A3 proteins act as sentinels in innate immunity against mobile DNA/RNA including viruses, while little is known about the effect of these proteins on nuclear DNA, in other words, host human genome. Recent studies have demonstrated that A3A impairs nuclear DNA under the condition of suppressing uracil DNA-glycosylase (UNG) which prevents base alterations by eliminating uracil from DNA and initiating the base-excision repair pathway^{18,19}.




Figure 1 | Expression of A3A, A3B wild-type and mutants, and AID. (A) Schematic of expression vectors. The consensus amino acid residues for zinc-coordinating motifs are shown. Substituted residues are shown in white. (B) Expression of HA-tagged proteins. Expression vectors were transfected into HEK293 cells, and cell lysates were analyzed by immunoblotting with anti-HA antibody (top panel) and anti- β -actin antibody (bottom panel) for loading control.

However, it is still unclear whether A3 proteins can induce somatic mutations into human genome with intact DNA repair systems. Here we first demonstrate that expression of A3B and A3A as well as AID can induce somatic mutations in genomic DNA in human cells even in the presence of UNG. We also find that high expression of A3B leads to somatic mutations in tumor-related genes. These data suggest that aberrant expression of A3B might be one of the active mechanisms that induce somatic mutations in cancer cells.

Results

A3 and AID induce hypermutations into foreign DNA. Besides A3A, we focused on A3B because it is localized predominantly in the nucleus^{20,21} and highly expressed in many types of cancer cells¹⁴ referring to microarray database (e.g., NextBio: <http://www.nextbio.com>). Previous studies have shown that A3B contains two enzymatically active CDAs in restricting HIV-1²², whereas only carboxyl-terminal CDA is responsible for inhibiting HBV replication^{23,24} and editing bacterial DNA²². A3B is also shown to restrict foreign DNA in mammalian cells²⁵, but it has not been tested which CDA is active in this context. First, to examine whether A3 and AID induce mutations in foreign DNA in human cells and which CDA is responsible for this DNA editing, we constructed amino- and/or carboxyl-terminal CDA mutants (H66R, H253R, and H66/253R) by site directed mutagenesis (Fig. 1a) and confirmed their expression in HEK293 cells by immunoblotting (Fig 1b). We transfected expression vectors for these together with EGFP expression vector into HEK293 cells and examined base substitutions in *EGFP* sequences. The expression vector for UNG inhibitor (UGI) was also co-transfected to avoid

UNG-triggered degradation of uracil-containing foreign DNA as described previously²⁵. We recovered total DNA from the cells 2 days after transfection and performed differential DNA denaturation PCR (3D-PCR) to efficiently recover edited DNA sequences²⁶. 3D-PCR is based on the principle that DNA sequences with fewer interstrand hydrogen bonds dissociates easier. If cytidine deamination takes place frequently, resulting AT-rich *EGFP* gene can be amplified at lower denaturation temperatures. Although PCR products were obtained from all samples at 92°C of denaturation temperature (Td), we obtained robust PCR products at 83.8°C of Td only from A3A-, A3B wild-type (WT)-, and AID-expressing cells (Fig 2a). Amplification of *EGFP* at the lowest Td was impaired in H66R-expressing cells compared to A3B WT-expressing cells and undetectable in H253R- or H66/253R-expressing cells (Fig 2a, bottom). To ascertain whether *EGFP* gene was actually hyperedited, we cloned and sequenced the amplicons at 83.8°C of Td. As can be seen from the mutation matrices, high levels of C/G to T/A transitions were introduced into *EGFP* sequences (Fig 2b). To compare the extent of baseline mutations and that of A3B-induced mutations, we also cloned and sequenced the amplicons at 94.0°C of Td. Mutation frequency of A3B-expressing cells were about 6 times higher than that of mock-transfected cells (Supplementary Fig. S1 online). The mutation frequency in H66R-expressing cells was approximately a half compared to that in A3B WT-expressing cells in the amplicons at the lowest Td (Fig 2c). These data suggest that carboxyl-terminal CDA of A3B is mainly responsible for foreign DNA editing, but both domains are requisite for full editing activity. It is worth noting that AID is also capable of inducing cytidine deamination into foreign DNA.

Human A3 proteins have preferred target dinucleotide sequences in the substrate DNA; A3A and A3B prefer to deaminate cytosine residues flanked by 5' thymine residue, 5'-TC, whereas A3G prefers to deaminate cytosine residues flanked by 5' cytosine residue, 5'-CC^{25,27–29}. We analyzed the context of C/G to T/A transitions in hyperedited *EGFP* sequences. We observed a strong bias toward deamination at 5'-TC dinucleotides in A3A-, A3B WT-, and H66R-expressing cells, but not in AID-expressing cells (Fig 2d). 5'-TC dinucleotide preference of A3B was also confirmed by sequencing amplicon at 94.0°C of Td which is supposed to be unbiased (Supplementary Fig. S1 online). These data suggest that the preference of editing sites in foreign DNA by A3s coincides with that seen in viral DNA.

A3A and A3B can edit genomic DNA in human cells. We next investigated whether A3 proteins induce C/G to T/A transitions into not only foreign DNA but also nuclear DNA in human cells. We first established a HEK293 cell line stably expressing EGFP (HEK293/EGFP) using retrovirus vector that carries *EGFP*. We transfected HEK293/EGFP cells with expression vectors for A3A, A3B WT or mutant (H66R, H253R, or H66/253R), or AID by lipofection, and then recovered total DNA from these cells after 7-day culture. We performed 3D-PCR of *EGFP* gene and obtained amplicons from A3A-, A3B WT-, H66R-, and AID-expressing cells at lower Td (Fig 3a). *EGFP* gene was recovered at Td as low as 86.3°C from A3B WT-expressing cells, while as low as 86.5°C from A3A-, H66R-, and AID-expressing cells. By contrast, *EGFP* gene was not amplified below Td of 87°C from cells transfected with mock, H253R or H66/253R. We repeated this procedure consisting of transfection, DNA extraction, and 3D-PCR three times and obtained similar results (Fig 3b). To unambiguously confirm the presence of C/G to T/A transitions, we cloned and sequenced amplicons obtained at the lowest Td in A3A-, A3B WT-, H66R-, and AID-expressing cells (Fig 3c). These analyses revealed approximately 2 to 5 C/G to T/A transitions per *EGFP* sequence from each sample (Fig 3d). The transitions were detected most frequently in A3A-expressing cells, and deaminase activity of H66R mutant was approximately a half




Figure 2 | Foreign DNA editing by A3A, A3B, and AID. (A) Agarose gel analyses of 3D-PCR products from HEK293 cells. Cells were transfected with expression vector for A3A, A3B wild-type or mutant, or AID together with pEGFP-N3 and pEF-UGI. Total DNA was recovered 2 days after transfection, and *EGFP* gene was amplified by 3D-PCR at the indicated denaturation temperatures (Td). (B) Mutation matrices of hyperedited *EGFP* sequences derived from cloned amplicons at 83.8°C of Td. “n” indicates the number of bases sequenced. We sequenced 5 clones (2,225 base pairs in total) in each group. (C) Frequencies of C/G to T/A transitions in hyperedited *EGFP* genes. C/G to T/A transitions per 1,000 sequenced base pairs are shown. (D) Dinucleotide contexts in foreign DNA editing. The rates of indicated dinucleotide sequence at the C to T transitions are shown. Asterisks indicate statistical significance in a χ^2 test ($p < 0.01$).

compared to that of A3B WT as seen in foreign DNA assays. The contexts of C/G to T/A transitions detected from the lowest Td amplicons in genomic DNA editing in A3-expressing cells were distinct from those in foreign DNA editing (Fig 3e). A preference for 5'-TC dinucleotide was not apparently observed, alternatively, 5'-GC dinucleotides were preferred in all samples. However, this bias fails to reach statistical significance ($p < 0.01$) in a χ^2 test. The preferred target sequences of AID editing were 5'-GC and 5'-AC dinucleotides as described by many prior studies^{27,30}. Mutation frequencies and preferred target sequence of A3B was also analyzed by using amplicons at 94.0°C of Td. Mutation frequency of A3B-expressing cells were about 3 times higher than that of mock-transfected cells (Supplementary Fig. S2 online). A preference for 5'-TC dinucleotide was impaired, compared to that in foreign DNA editing assays (Supplementary Fig. S2 online). Our results reveal that in addition to AID, A3A and A3B can induce C/G to T/A transitions into human nuclear DNA without repressing proofreading enzymes (e.g., UNG). Mutation frequencies were 6 to 9 per 1000 base pairs in A3A-, A3B WT-, and AID-expressing cells, and much less frequent compared to those in foreign DNA editing. As seen with foreign DNA editing, carboxyl-terminal CDA is mainly responsible for catalytic activity but not sufficient for full editing activity.

The preference context of genomic DNA editing by A3A and A3B is different from that of viral or foreign DNA editing.

Deep sequencing reveals hyperediting of human genomic DNA by A3 proteins. Amplicon sequencing by next-generation sequencer has enabled to detect extremely low levels of mutations of targeted regions in genomic DNA. To verify more certainly that A3 proteins edit human nuclear DNA, we performed deep sequencing of A3-expressing cells. HEK293/EGFP cells were transfected with an empty vector or expression vectors for A3A, A3B WT, H66/253R, or AID by lipofection, and total DNA were extracted after 7-day culture. We amplified a portion of *EGFP* gene with 443 base pair length (from thymine 56 to cytosine 498) by conventional PCR protocol, not by 3D-PCR, and performed amplicon sequencing with the coverage of 1337 to 2654 reads per sample. This analysis revealed that extremely large numbers of nucleotides were substituted over the full length of amplicons in A3A-, A3B WT-, and AID-expressing cells, whereas very few mutations were detected in mock and H66/253R-expressing cells (Supplementary Table 1 online). C/G to T/A transitions were observed most frequently in A3A-expressing cells as variation rates reach approximately 7% at the maximum, while below 3% at most in A3B- and AID-expressing cells (Fig 4a




Figure 3 | Hypermutations in *EGFP* genes integrated in genomic DNA of HEK293 cells. (A) Agarose gel analyses of 3D-PCR products of *EGFP* genes extracted from HEK293/*EGFP* cells. Cells were transfected with expression vector for A3A, A3B wild-type or mutant, or AID. Total DNA was recovered 7 days after transfection and *EGFP* genes were amplified by 3D-PCR at the indicated denaturation temperatures (Td). (B) Distributions of the lowest denaturation temperatures for positive PCR amplification in each sample. Each circle represents independent experiment consisting of transfection, DNA extraction, and 3D-PCR. (C) Mutation matrices of hyperedited *EGFP* sequences derived from cloned PCR products at Td lower than 87°C. “n” indicates the number of bases sequenced. We sequenced 25 clones (11,125 base pairs in total) in each group. (D) Frequencies of C/G to T/A transitions in hyperedited *EGFP* genes. C/G to T/A transitions per 1,000 sequenced base pairs are shown. (E) Dinucleotide contexts in genomic DNA editing. The rates of indicated dinucleotide sequence at the C to T transitions are shown. Deviations in the editing contexts do not reach statistical significance ($p < 0.01$) in a χ^2 test.

and Supplementary Table 1 online). The mutation frequency analysis revealed that large numbers of C/G to T/A substitutions were induced in A3A-, A3B-, and AID-expressing cells, whereas other types of base substitutions were very few (Fig 4b). These results are similar to the data obtained by 3D-PCR and clonal sequencing of A3- and AID-expressing cells, and further demonstrated that A3A and A3B as well as AID can induce C/G to T/A transitions into genomic DNA in human cells with intact DNA repair systems. Dinucleotide preference of target sequence for deamination by A3A, A3B and AID was also analyzed, however, we did not find any preference in this experiment (Fig. 4C), suggesting the difference between foreign DNA editing and genomic DNA editing.

Expression of A3B and somatic mutations in lymphoma cells. Although AID has been reported to play important roles in lymphoma-genesis by inducing mutations in both Ig and non-Ig genes^{11,12,31–34}, AID-independent mechanisms are also suggested, because AID is not expressed in all types of B-cell lymphomas^{31,35}. We hypothesized that A3 may contribute to somatic mutations in some lymphoma cells. To examine this hypothesis, we first determined expression levels of A3A, A3B, and AID by quantitative RT-PCR in several B-cell lymphoma cell lines using peripheral blood lymphocytes (PBL) as control (Fig 5a). Our analysis revealed that A3B was highly expressed in 3 of 4 cell lines, particularly, markedly high in KIS1 cells, whereas expression of A3A transcripts was not detected in any




Figure 4 | Deep sequencing of *EGFP* genes in genomic DNA. (A) The distributions of C/G to T/A substitutions in the *EGFP* sequences. Total DNA was recovered from HEK293/EGFP cells 7 days after transfection with expression vector for A3A, A3B wild type or H66/253R or AID. We amplified a portion of *EGFP* sequence from thymine 47 to cytosine 504 (top schematic) by PCR with high-fidelity polymerase and sequenced the amplicons by GS-junior bench top system (Roche). Sequence data were analyzed with equipped software. “Coverage” indicates the total numbers of sequenced reads. (B) Frequencies of base substitutions in hyperedited *EGFP* genes. Base substitutions were classified to 6 groups and substituted base number of each group per 1,000 sequenced base pairs are shown. (C) Dinucleotide contexts in genomic DNA editing. The rates of indicated dinucleotide sequence at the C to T transitions are shown. Deviations in the editing contexts do not reach statistical significance ($p < 0.01$) in a χ^2 test.

lymphoma cell lines consistent with prior work suggesting myeloid specificity^{25,36}. *AID* transcripts were detected in 2 of 4 cell lines, which is consistent with previous studies^{31,32,37}. We also examined expression of *A3B* in two lymph node samples of diffuse large B-cell lymphoma, and found that *A3B* is actually expressed (supplementary Fig. 3 online).

To investigate the correlation between *A3B* expression and frequency of somatic mutations, we next performed direct sequencing of *cMYC*, *PAX5*, and *A20* genes which are exemplary genes mutated frequently in B-cell lymphoma^{33,38}. We compared mutation frequencies of these genes in SUDHL-6 and KIS-1, because the expression of *A3B* was the lowest in the former and the highest in the latter, while *AID* was not expressed in either cell line. DNA sequences between exon 1 and intron 1 of these three genes were analyzed (899 base pairs of *cMYC*, 1550 base pairs of *Pax5*, and 1088 base pairs of *A20*), since it has been reported that somatic mutations induced by cytosine deaminases were concentrated within 2 kb downstream from transcription initiation sites^{33,34}. We found nine mutations within investigated sequences of *cMYC* and *PAX5* in KIS-1, but not in SUDHL-6, in which five of nine mutations detected were C/G to T/A transitions. On the other hand, no mutation was detected within sequenced region of *A20* in either cells (Fig 5b). To analyze ongoing mutations

in the genome in individual cells, we next sequenced the same region of *cMYC* sub-cloned from KIS-1 and SUDHL-6, and found several more C to T mutations in KIS-1 cells, but not in SUDHL-6 cells (Supplementary Fig. S4 online). We next determined expression of these tumor-related genes by quantitative RT-PCR and found that the transcripts of *cMYC* and *PAX5* were highly expressed in both SUDHL6 and KIS1 cells as compared to PBL, whereas *A20* was less transcribed in these lymphoma cells. These results suggest that high expression of *A3B* resulted in accumulation of base alterations, especially C/G to T/A transitions, in actively transcribed tumor-related genes in lymphoma cells.

To ascertain more definitely that *A3B* can edit tumor-related genes in lymphoma cells, we introduced *A3B* into a lymphoma cell line and analyzed somatic mutations in *cMYC*. SUDHL-6 cells were transfected with expression vector for *A3B* WT, H66/253R, or mock by electroporation and total DNA was extracted after 7-day culture. With 3D-PCR analysis of *cMYC*, we obtained the amplicon from only *A3B* WT-expressing cells at the lower Td (Fig 6a). Clonal sequencing of amplicons at 85.9°C revealed 2 to 7 nucleotide substitutions per strand, and more than 80% of these mutations were C/G to T/A transitions, with a preference for 5'-GC dinucleotide sites (Fig 6b and c). We also sequenced the amplicons at 94.0°C of Td and




Figure 5 | Expression of A3B and somatic mutations in oncogenes in human lymphoma cell lines. (A) Quantitative RT-PCR for A3A, A3B, and AID in lymphoma cell lines. The levels of target cDNA were normalized to the endogenous hypoxanthine phosphoribosyl transferase 1 (*HPRT1*) and then compared to those in peripheral blood lymphocytes. (B) Mutational analyses of *C-myc*, *Pax5*, and *A20* in SUDHL6 and KIS1 cells. We recovered total DNA from the cells and amplified the sequence between exon1 and intron1 of *C-myc*, *Pax5* and *A20* by PCR and performed direct sequencing of the amplicons. Locations of somatic mutations are shown below the loci with their positions. (C) The expression levels of transcripts of *C-myc*, *Pax5*, and *A20* in KIS1 and SUDHL6 cells. Quantitative RT-PCR was similarly performed with (a).

found A3B-induced C/G to T/A transitions without 5'-TC dinucleotide preference (supplementary Fig. 5 online). These data demonstrate that expression of A3B can induce somatic mutations into actively transcribed tumor-related genes in lymphoma cells.

Discussion

To date, most studies on A3 proteins have focused on their abilities as antiviral or antitransposon factors, whereas the capability of A3 proteins to induce mutations into genomic DNA in host cells has been scarcely verified. In contrast, many studies have elucidated that AID induces somatic mutations into not only Ig genes, but also tumor-related genes in human cells and that ubiquitous expression of AID in mice leads to cancers of various organs as well as lymphomas, with the accumulation of nucleotide alterations^{9–13}. Thus, AID has been considered as the only DNA cytosine deaminase that can induce somatic mutations into human genome and has potential to cause cancers or hematologic malignancies.

Suspène *et al.* have recently reported that hyperediting of both mitochondrial and nuclear DNA was detected in human cells defective for UNG derived from hyper IgM syndrome patients and demonstrated that A3A-induced mutations in nuclear DNA are detectable under the condition of suppressing UNG in human cells¹⁹. In their report, deamination of nuclear DNA was not observed in cells expressing other A3 proteins or in cells expressing A3A without UNG suppression. Furthermore, Landry *et al.* have reported that expression of A3A together with UGI in mammalian cell lines resulted in breaking of DNA and activation of DNA damage response in a deaminase-dependent manner¹⁸. In these two reports, the effect on genomic integrity by A3A was dependent on the presence of

UGI. Thus, there has been no direct evidence that A3 proteins induce mutations in genomic DNA in the cells with intact DNA repair systems.

In this study, we demonstrate that A3A and A3B as well as AID can induce C/G to T/A transitions into nuclear DNA without suppressing UNG by two different assays, 3D-PCR and deep sequencing. We assume that increased number of cytidine deamination catalyzed by highly expressed A3A or A3B exceeded the processivity of DNA repair enzymes such as UNG and resulted in leaving C/G to T/A transitions in nuclear DNA. Mutation frequencies were considerably lower compared to Suspène's report. However, Yoshikawa *et al.* reported that AID induced hypermutations into an actively transcribed gene in fibroblasts and that the mutation frequency was approximately 4 to 6 per 1000 base pairs¹⁰, almost to the same extent as our results. Hence the frequency of mutations induced by cytidine deaminases into nuclear DNA is probably this extent or less in the cells with intact DNA repair systems.

We also find that A3B is highly expressed in several lymphoma cell lines and that the cells expressing high levels of A3B actually possess somatic mutations, especially C/G to T/A transitions, in actively transcribed tumor-related genes. Furthermore, we reveal that introduction of A3B into lymphoma cells induces the accumulation of C/G to T/A transitions in *cMYC* gene. This is the first report that suggests the involvement of A3B in inducing somatic mutations of oncogenes in tumor cells. Together with the microarray database of A3B expression in miscellaneous cancer cell lines¹⁴ (NextBio: <http://www.nextbio.com>), it is possible that A3B may induce somatic mutations into tumor related genes in various types of cancers.

Several questions remain open. First, it remains unclear what is preferred target sequences of A3 proteins in genomic DNA. Because




Figure 6 | A3B induced somatic mutations into *c-myc* gene in human lymphoma cells. (A) Agarose gel analyses of 3D-PCR products of *c-Myc* genes in SUDHL6. We transfected expression vector for A3B wild-type or H66/253R or empty vector and recovered total DNA 7 days after transfection. *C-myc* genes were amplified by 3D-PCR at the indicated denaturation temperatures (Td). (B) Clonal sequencing of amplicons from A3B-WT expressing SUDHL6 cells. We sequenced 11 clones (5104 base pairs in total). Seventy six bases from thymine 310 to adenine 385 in which mutations are concentrated among sequenced 464 base pairs are shown. The numbers of C/G to T/A substitutions in sequenced 464 base pair length are shown at the right end. (C) Dinucleotide contexts of somatic mutations in *c-Myc* gene by A3B. The rates of indicated dinucleotide sequence at the C to T transitions are shown. Asterisks indicate statistical significance in a χ^2 test ($p < 0.01$).

in several cancers such as breast cancer and melanoma, 5'-TC is the most prevalent target in C to T base substitutions, A3 is the most potential candidate to induce these mutations^{25,28}. However, in our results, neither A3A nor A3B had a definite preference of editing site in nuclear DNA editing, whereas a preference for 5'-TC dinucleotide was observed in foreign DNA editing as previously reported. It is possible that A3A and A3B have no distinct favorite context in nuclear DNA editing, unlike viral and bacterial DNA editing, because human genomic DNA is more profoundly protected in transcription than viral or bacterial DNA and is under survey of DNA repair systems. However, Suspene *et al.* reported that target contexts of cytidine deamination in A3A+UGI-expressing cells were 5'-TC and 5'-CC dinucleotides, which were identical to the contexts of viral or bacterial DNA editing¹⁹. We assume that this discrepancy might be attributable to cell types or expression levels in cells. Hence, further analyses should be required to clarify the favorite target contexts of A3 proteins in nuclear DNA editing. The second question is how transcriptional control and post-translational modification of A3 proteins regulate A3 activity. Because the molecules that possess a capability of editing nuclear DNA threaten cell homeostasis, expression and activity of A3A and A3B must be strictly controlled. AID is known to be regulated at multiple steps³⁹, for example, transcriptional regulation^{40–42}, post-transcriptional regulation by micro-RNA^{43,44}, regulation of intracellular localization^{45,46}, and phosphorylation by PKA^{47,48}. In contrast to AID, little is known about how A3 proteins are regulated. It has been

reported that A3A is abundantly expressed in CD14+ monocytes and upregulated by interferon- α stimulation^{25,49,50}. Meanwhile, it is not clear where A3B is expressed normally^{25,42,49,50} and how it is regulated. As for post-translational modification, we previously reported that PKA-mediated phosphorylation of A3G regulates the interaction between A3G and HIV Vif⁵¹. To better understand the physiological roles of A3 proteins, it is important to elucidate how their expression and activity are regulated. The last question is whether A3 proteins can serve as an “initiator” of tumorigenesis. Our results suggest A3B indeed induces somatic mutations into genomic DNA in various human tumor cells, however, it is unclear whether A3B proteins impair genomic DNA from the early stage of oncogenesis. To address this question, hereafter, histopathological and genetic analyses of transgenic mouse constitutively expressing A3 proteins are necessary.

In conclusion, our findings provides the first evidence that A3A and A3B can induce C/G to T/G transitions into genomic DNA without suppressing DNA repair system. Our data also show that high expression of A3B is related to mutation frequencies of oncogenes in lymphoma cells. Our results suggest that A3B is an oncogene, like AID, which may have the capacity to evoke genomic instability through base substitutions in human cells. Further studies will be required to test whether endogenous A3B is capable of impairing genomic integrity as a DNA mutator and contributing to the development of human cancers and hematologic malignancies.



Methods

DNA constructs and cell lines. Plasmids containing coding sequence of human A3A and A3B were kindly provided by Dr. Kenzo Tokunaga²¹. Expression vectors for HA-tagged A3A, A3B and AID were generated by sub-cloning of coding sequences into pCAG-GS vector. A3B catalytic domain mutants (H66R, H253R, and H66/253R) were generated by KOD-plus mutagenesis Kit (Toyobo). Expression vector for Uracil-DNA glycosylase inhibitor, pEF-UGI was kindly provided by Dr. Ruben S Harris²⁵. HEK293 and HEK293T cells were maintained with Dulbecco's modified Eagle's medium containing 10% of fetal bovine serum (FBS) and penicillin, streptomycin, and glutamine (PSG). All B-cell lymphoma cell lines were maintained with RPMI1640 containing 10% FBS and PSG. Retrovirus containing *EGFP* sequence was produced by co-transfection of pMLV gag-pol, VSV-G, and pDON-EGFP into HEK293T cells. HEK293/EGFP cells were generated by retroviral transduction of *EGFP* and selection of 1 mg/ml G418 for two months.

Immunoblotting. HEK293 cells were transfected with expression vector for A3A, A3B wild-type or mutant (H66R, H253R or H66/253R) or AID, and lysed with RIPA buffer (50 mM Tris-HCl pH7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton-X, 0.1% SDS, 0.1% DOC) after 2-day culture. After centrifugation at 20,000 x g for 15 min, supernatant was mixed with sample buffer (Biorad), boiled for 5 minutes, resolved on 12% (w/v) polyacrylamide gel, transferred to PVDF membrane (Immobilon, Millipore), and analyzed by standard immunoblotting procedure with anti-HA monoclonal antibody (12CA5, Roche) or anti- β -actin monoclonal antibody (AC-15, Sigma).

3D-PCR and clonal sequencing. For foreign DNA editing assay, HEK293 cells were transfected with pEGFP-N3, pEF-UGI, and expression vector for A3A, A3B WT or mutant, or AID by using Eugene HD (Roche). After two-day culture, total DNA was extracted by using Quick Gene DNA whole blood kit (Fuji Film). First round PCR was performed with primers listed in Supplementary Table S2 using rTaq DNA polymerase (Takara), with the following reaction profile; 30 s at 94°C, 25 cycles of 30 s at 94°C, 40 s at 62°C, and 90 s at 72°C followed by 10 min at 72°C. The amplicons were separated by electrophoresis on 1% (w/v) agarose gel, and extracted from the gel using Qiaquick Gel Extraction kit (Qiagen). We used 25 ng of first-round PCR products as template for nested PCR using Hotstar Hifidelity DNA polymerase (Qiagen), with the following reaction profile; 5 min at 95°C, 35 cycles of 15 s at 83–92°C, 60 s at 62°C, 80 s at 72°C, followed by 10 min at 72°C. The amplicons derived at 83.8°C were cloned into pT7-blue vector (Novagen). For nuclear DNA editing assay, HEK293/EGFP cells were transfected with expression vector for A3A, A3B WT or mutants, or AID using Eugene HD (Roche). Seven days after transfection, we extracted total DNA from these cells with the same method of foreign DNA editing assay. First round PCR was performed using Advantage HF2 polymerase kit (Clontech), with the following reaction profile; 1 min at 94°C, 30 cycles of 30 s at 94°C followed by 2 min at 68°C, followed by 3 min at 68°C. We used 25 ng of first-round PCR products for nested PCR using Hotstar Hifidelity DNA polymerase (Qiagen) with the following reaction profile; 5 min at 95°C, 35 cycles of 15 s at 86–89°C, 60 s at 62°C, and 80 s at 72°C, followed by 10 min at 72°C. The amplicons derived at 86.5°C and 83.8°C were cloned into pT7-blue vector (Novagen). For *c-myc* gene editing assay in lymphoma cells, we transfected SUDHL6 cells with expression vectors for A3B WT or H66/253R by electroporation using Nucleofector (Amaxa) and extracted total DNA from the cells 7 days after transfection. First round PCR and gel extractions of amplicons were performed with the same methods of nuclear DNA editing assay. We used 25 ng of first-round PCR products for nested PCR using Hotstar Hifidelity DNA polymerase (Qiagen), with the following reaction profile; 5 min at 95°C, 35 cycles of 15 s at 85–88°C, 60 s at 62°C, 80 s at 72°C, followed by 10 min at 72°C. The amplicons derived at 85.3°C were cloned into pT7-blue vector (Novagen) and sequenced using 3130xl Genetic Analyzer (Applied Biosystems).

Deep sequencing. Total DNA was extracted from HEK293/EGFP transfected with expression vectors for A3A, A3B WT or H66/253R or AID 7 days after transfection. A portion of *EGFP* gene with 443 base pair length, from thymine 56 to cytosine 498, was amplified with the primers listed in Supplementary Table 2 using Advantage HF2 polymerase kit (Clontech), with the following reaction profile; 1 min at 94°C, 30 cycles of 30 s at 94°C followed by 2 min at 68°C, and followed by 3 min at 68°C. The amplicons were separated by electrophoresis on 1% (w/v) agarose gel, and extracted from the gel using Qiaquick Gel Extraction Kit (Qiagen). Purified amplicons were sequenced using GS junior bench top system (Roche) according to the manufacturer's protocol and analyzed with equipped software, GS Amplicon Variant Analyzer.

Lymphoma cell lines and patient samples. Four B-cell lymphoma cell lines (SUDHL6, K1S1, KM-H2, and Granta519) were cultured in RPMI1640 containing 10% of fetal bovine serum (FBS) and penicillin, streptomycin, and glutamine (PSG). We extracted total DNA from these cells by using Quick Gene DNA whole blood kit (Fuji Film) and total RNA by using mir Vana miRNA isolation kit (Ambion). Tumor biopsy specimens prior to treatment were obtained from two patients with diffuse large B-cell lymphoma. The study was approved by the Kyoto University Institutional Review Board and written informed consent was obtained from each patient. Total RNA were extracted similarly to lymphoma cell lines. Naive B-cells were isolated from healthy donor's peripheral blood by using MACS[®] naive B cell isolation kit (Miltenyi Biotec).

Quantitative RT-PCR. Complementary DNA was synthesized from 200 ng of total RNA using Revertra Ace qPCR RT Master Mix (Toyobo). Real-time PCR were performed with Thunderbird SYBR qPCR Mix (Toyobo) according to manufacturer's protocol. Target cDNAs were normalized to the endogenous expression level of the house keeping reference gene for hypoxanthine-guanine phosphoribosyl transferase 1 (*HPRT1*) or glyceraldehyde 3-phosphate dehydrogenase (*GAPDH*). All primers for real-time PCR are listed in Supplementary Table 2.

Sequencing of oncogenes from lymphoma cell lines. We amplified portions of *C-myc*, *Pax5*, and *A20* from with the primers listed in Supplementary Table 2 using Advantage HF2 polymerase kit (Clontech), with the following reaction profile; 1 min at 94°C, 30 cycles of 30 s at 94°C followed by 4 min at 68°C, and followed by 3 min at 68°C. The amplicons were separated by electrophoresis on 1% (w/v) agarose gel, extracted from the gel using Qiaquick Gel Extraction kit (Qiagen), and sequenced using 3130xl Genetic Analyzer (Applied Biosystems). In *c-myc* clonal sequencing, the amplicon was subcloned into pTA2-vector (TOYOBO) and subsequently sequenced.

- Hahn, W. C. & Weinberg, R. A. Rules for making human tumor cells. *N Engl J Med* **347**, 1593–603 (2002).
- Pleasant, E. D. *et al.* A comprehensive catalogue of somatic mutations from a human cancer genome. *Nature* **463**, 191–6 (2010).
- Bronner, C. E. *et al.* Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. *Nature* **368**, 258–61 (1994).
- Greenman, C. *et al.* Patterns of somatic mutation in human cancer genomes. *Nature* **446**, 153–8 (2007).
- Prickett, T. D. *et al.* Analysis of the tyrosine kinase in melanoma reveals recurrent mutations in ERBB4. *Nat Genet* **41**, 1127–32 (2009).
- Macduff, D. A. & Harris, R. S. Directed DNA deamination by AID/APOBEC3 in immunity. *Curr Biol* **16**, R186–9 (2006).
- Coticello, S. G. The AID/APOBEC family of nucleic acid mutators. *Genome Biol* **9**, 229 (2008).
- Muramatsu, M. *et al.* Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. *Cell* **102**, 553–63 (2000).
- Matsumoto, Y. *et al.* Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. *Nat Med* **13**, 470–6 (2007).
- Yoshikawa, K. *et al.* AID enzyme-induced hypermutation in an actively transcribed gene in fibroblasts. *Science* **296**, 2033–6 (2002).
- Okazaki, I. M. *et al.* Constitutive expression of AID leads to tumorigenesis. *J Exp Med* **197**, 1173–81 (2003).
- Pasqualucci, L. *et al.* AID is required for germinal center-derived lymphomagenesis. *Nat Genet* **40**, 108–12 (2008).
- Endo, Y. *et al.* Activation-induced cytidine deaminase links between inflammation and the development of colitis-associated colorectal cancers. *Gastroenterology* **135**, 889–98, 898 e1–3 (2008).
- Jarmuz, A. *et al.* An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. *Genomics* **79**, 285–96 (2002).
- Goila-Gaur, R. & Strebel, K. HIV-1 Vif, APOBEC, and intrinsic immunity. *Retrovirology* **5**, 51 (2008).
- Mangeat, B. *et al.* Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. *Nature* **424**, 99–103 (2003).
- Bogerd, H. P. *et al.* Cellular inhibitors of long interspersed element 1 and Alu retrotransposition. *Proc Natl Acad Sci U S A* **103**, 8780–5 (2006).
- Landry, S., Narvaiza, I., Linfesty, D. C. & Weitzman, M. D. APOBEC3A can activate the DNA damage response and cause cell-cycle arrest. *EMBO Rep* **12**, 444–50 (2011).
- Suspène, R. *et al.* Somatic hypermutation of human mitochondrial and nuclear DNA by APOBEC3 cytidine deaminases, a pathway for DNA catabolism. *Proc Natl Acad Sci U S A* **108**, 4858–63 (2011).
- Lackey, L. *et al.* APOBEC3B and AID have similar nuclear import mechanisms. *J Mol Biol* **419**, 301–14 (2012).
- Kinomoto, M. *et al.* All APOBEC3 family proteins differentially inhibit LINE-1 retrotransposition. *Nucleic Acids Res* **35**, 2955–64 (2007).
- Bogerd, H. P., Wiegand, H. L., Doehle, B. P. & Cullen, B. R. The intrinsic antiretroviral factor APOBEC3B contains two enzymatically active cytidine deaminase domains. *Virology* **364**, 486–93 (2007).
- Suspène, R. *et al.* Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. *Proc Natl Acad Sci U S A* **102**, 8321–6 (2005).
- Bonvin, M. & Greeve, J. Effects of point mutations in the cytidine deaminase domains of APOBEC3B on replication and hypermutation of hepatitis B virus in vitro. *J Gen Virol* **88**, 3270–4 (2007).
- Stenglein, M. D., Burns, M. B., Li, M., Lengyel, J. & Harris, R. S. APOBEC3 proteins mediate the clearance of foreign DNA from human cells. *Nat Struct Mol Biol* **17**, 222–9 (2010).
- Suspène, R., Henry, M., Guillot, S., Wain-Hobson, S. & Vartanian, J. P. Recovery of APOBEC3-edited human immunodeficiency virus G→A hypermutants by differential DNA denaturation PCR. *J Gen Virol* **86**, 125–9 (2005).



27. Vartanian, J. P. *et al.* Massive APOBEC3 editing of hepatitis B viral DNA in cirrhosis. *PLoS Pathog* **6**, e1000928 (2010).
28. Bishop, K. N. *et al.* Cytidine deamination of retroviral DNA by diverse APOBEC proteins. *Curr Biol* **14**, 1392–6 (2004).
29. Harris, R. S. *et al.* DNA deamination mediates innate immunity to retroviral infection. *Cell* **113**, 803–9 (2003).
30. Beale, R. C. *et al.* Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. *J Mol Biol* **337**, 585–96 (2004).
31. Greeve, J. *et al.* Expression of activation-induced cytidine deaminase in human B-cell non-Hodgkin lymphomas. *Blood* **101**, 3574–80 (2003).
32. Deutsch, A. J. *et al.* MALT lymphoma and extranodal diffuse large B-cell lymphoma are targeted by aberrant somatic hypermutation. *Blood* **109**, 3500–4 (2007).
33. Pasqualucci, L. *et al.* Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. *Nature* **412**, 341–6 (2001).
34. Kotani, A. *et al.* A target selection of somatic hypermutations is regulated similarly between T and B cells upon activation-induced cytidine deaminase expression. *Proc Natl Acad Sci U S A* **102**, 4506–11 (2005).
35. Smit, L. A. *et al.* Expression of activation-induced cytidine deaminase is confined to B-cell non-Hodgkin's lymphomas of germinal-center phenotype. *Cancer Res* **63**, 3894–8 (2003).
36. Chen, H. *et al.* APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. *Curr Biol* **16**, 480–5 (2006).
37. Mottok, A., Hansmann, M. L. & Bräuninger, A. Activation induced cytidine deaminase expression in lymphocyte predominant Hodgkin lymphoma. *J Clin Pathol* **58**, 1002–4 (2005).
38. Kato, M. *et al.* Frequent inactivation of A20 in B-cell lymphomas. *Nature* **459**, 712–6 (2009).
39. Delker, R. K., Fugmann, S. D. & Papavasiliou, F. N. A coming-of-age story: activation-induced cytidine deaminase turns 10. *Nat Immunol* **10**, 1147–53 (2009).
40. Crouch, E. E. *et al.* Regulation of AID expression in the immune response. *J Exp Med* **204**, 1145–56 (2007).
41. Gonda, H. *et al.* The balance between Pax5 and Id2 activities is the key to AID gene expression. *J Exp Med* **198**, 1427–37 (2003).
42. Pauklin, S., Sernández, I. V., Bachmann, G., Ramiro, A. R. & Petersen-Mahrt, S. K. Estrogen directly activates AID transcription and function. *J Exp Med* **206**, 99–111 (2009).
43. Teng, G. *et al.* MicroRNA-155 is a negative regulator of activation-induced cytidine deaminase. *Immunity* **28**, 621–9 (2008).
44. de Yébenes, V. G. *et al.* miR-181b negatively regulates activation-induced cytidine deaminase in B cells. *J Exp Med* **205**, 2199–206 (2008).
45. Ito, S. *et al.* Activation-induced cytidine deaminase shuttles between nucleus and cytoplasm like apolipoprotein B mRNA editing catalytic polypeptide 1. *Proc Natl Acad Sci U S A* **101**, 1975–80 (2004).
46. Patenaude, A. M. *et al.* Active nuclear import and cytoplasmic retention of activation-induced deaminase. *Nat Struct Mol Biol* **16**, 517–27 (2009).
47. Basu, U. *et al.* The AID antibody diversification enzyme is regulated by protein kinase A phosphorylation. *Nature* **438**, 508–11 (2005).
48. McBride, K. M. *et al.* Regulation of class switch recombination and somatic mutation by AID phosphorylation. *J Exp Med* **205**, 2585–94 (2008).
49. Koning, F. A. *et al.* Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. *J Virol* **83**, 9474–85 (2009).
50. Berger, G. *et al.* APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells. *PLoS Pathog* **7**, e1002221 (2011).
51. Shirakawa, K. *et al.* Phosphorylation of APOBEC3G by protein kinase A regulates its interaction with HIV-1 Vif. *Nat Struct Mol Biol* **15**, 1184–91 (2008).

Acknowledgments

We thank R. Harris for thoughtful feedback and for UGI vector, and K. Tokunaga for A3A and A3B vectors.

Author contributions

M.S. performed most of the experiments, analyzed the data and wrote the manuscript; I.K., M.M., T.S. and K.T. performed sequencing of lymphoma cell lines; K.S. and N.K. wrote the manuscript; M.K. established q-PCR; A.T.K. designed the experiments and wrote the manuscript.

Additional information

Supplementary information accompanies this paper at <http://www.nature.com/scientificreports>

Competing interest statements: The authors declare no competing financial interests.

License: This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-sa/3.0/>

How to cite this article: Shinohara, M. *et al.* APOBEC3B can impair genomic stability by inducing base substitutions in genomic DNA in human cells. *Sci. Rep.* **2**, 806; DOI:10.1038/srep00806 (2012).